In transplant-eligible patients with newly diagnosed multiple myeloma (MM), induction therapy followed by peripheral blood stem cell (PBSC) collection with granulocyte-colony-stimulating factor (G-CSF), high-dose chemotherapy (HDCT) with melphalan and autologous blood stem cell transplantation (ABSCT) is a standard-of-care [1–3]. The gene discussed is CSF3; the disease is AL amyloidosis.